Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06253702 · ClinicalTrials.gov registry record · Phase 4
Brain Blood Flow Responses to Stress: Sex Differences
A Phase 4 study of Cerebrovascular Disorders, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT06253702: Completed Phase 4 study of Cerebrovascular Disorders, sponsored by University of Wisconsin, Madison.
NCT06253702 is a Phase 4 study of Cerebrovascular Disorders that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 22 participants, below the 1,094-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06253702, a Phase 4 study of Cerebrovascular Disorders, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Twenty-six otherwise healthy adults between 18-40 years of age composed of 13 males and 13 females will be enrolled in this study to determine how sex and sex hormones influence cerebral blood flow (CBF) control in healthy young adults without confounds of age or disease. Participants can expect to be on study for approximately 16 days.
Primary Outcome
Hypoxia condition will be measured twice via MRI during the first set of study visits under hormone suppression. Reported here is the CBF under hypoxia for the placebo group as compared to the CBF under hypoxia for the Indo group.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Anastrozole
- DRUG Indomethacin
- DRUG Testosterone gel
- DRUG Orilissa
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 4 |
What the finished NCT06253702 record still lists
NCT06253702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,094-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cerebrovascular Disorders appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06253702 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06253702 about?
NCT06253702 is a clinical study titled "Brain Blood Flow Responses to Stress: Sex Differences". Twenty-six otherwise healthy adults between 18-40 years of age composed of 13 males and 13 females will be enrolled in this study to determine how sex and sex hormones influence cerebral blood flow (CBF) control in healthy young adults without confounds of age or disease. Participants can expect to ...
What is the current status of trial NCT06253702?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2024-07-24. Estimated completion is 2025-05-31.
What conditions does trial NCT06253702 study?
This clinical trial studies the following conditions: Cerebrovascular Disorders.
What interventions are being tested in trial NCT06253702?
The interventions under investigation include: Placebo (DRUG), Anastrozole (DRUG), Indomethacin (DRUG), Testosterone gel (DRUG), Orilissa (DRUG).
Who is sponsoring clinical trial NCT06253702?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06253702 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebrovascular Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06253702's enrollment target sits among peer trials
22 8th of 8 higher than 1 of 8 other Cerebrovascular Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cerebrovascular Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cerebrovascular Health and Resilience in Midlife
RECRUITING · NA
-
Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy
RECRUITING · Phase 1
-
Brain, Blood And Clot or Tissue Registry And Collaboration
RECRUITING
-
The Jackson Heart Study of Cardiovascular Disease Among African Americans
ACTIVE NOT RECRUITING
-
Epidemiology of Sleep-Disordered Breathing in Adults
ACTIVE NOT RECRUITING
-
pRESET for Occlusive Stroke Treatment
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI